Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Income Before Tax

Profit after all operating and non-operating items but before income tax.

Ovid Therapeutics Inc.NASDAQ: OVID

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$16.99M, compared with -$10.24M a year earlier. Trailing-twelve-month income before tax was -$24.17M.

Context

  • Income before tax amounted to 240.1% of revenue in FY2025, down 4430.0 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$16.99M or moves back toward the trailing-twelve-month quarterly average of -$6.04M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.99M-275.8% QoQ
Last fiscal yearDec 2025
-$17.41M+34.1% YoY
LTMMar 2026
-$24.17M+3.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.0%——
1 year+34.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(17.41M) USD
Year-over-year change
+34.1%

Income Before Tax vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 income before tax of -$24.17M is the 2nd highest of the 11 companies compared; the peer median is -$135.08M.
  • Its year-over-year change of +3.2% is the 5th highest of 11, against a peer median of -16.3%.
  • Income before tax amounts to 339.3% of revenue for OVID, versus a peer median of 319.3%.
OVID Competitors Peer median
Income Before Tax for OVID and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$66.24M +249.9%—455.6%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24.17M +3.2%—339.3%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$87.5M +19.9%——
NGNENeurogene Inc.LTM Mar 2026-$98.64M -22.0%——
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$116.52M -38.7%—319.3%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$120.53M +28.0%—151.1%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-$149.63M -61.4%—2728.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$171.05M -431.8%—533.2%
WVEWave Life Sciences Ltd.LTM Mar 2026-$183.59M -63.4%—255.7%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$209.38M +18.9%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$605.54M -10.7%—90.5%
Peer median (excluding OVID) -$135.08M-16.3%—319.3%

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue208.38M1.5M392K566K7.25M
Cost of Revenue0000300K
Gross Profit208.38M1.5M392K566K6.95M
Gross Margin100.0%100.0%100.0%100.0%95.9%
Research & Development46.94M24.62M28.59M36.77M25.58M
Selling, General & Admin37.23M32.43M29.59M25.68M24.11M
Operating Expenses84.17M57.05M59.67M62.45M49.39M
Depreciation & Amortization237.08K1.38M568K613K300K
EBITDA124.45M(54.17M)(57.01M)(57.77M)(17.11M)
EBITDA Margin59.7%-3604.5%-14544.1%-10207.1%-236.0%
Operating Income124.21M(55.55M)(59.28M)(61.89M)(42.44M)
Operating Margin59.6%-3696.4%-15122.7%-10933.7%-585.2%
Interest Income004.9M3.9M0
Interest Expense00000
Other Income / Expenses(45.69K)1.38M6.94M35.45M25.03M
Income Before Tax124.16M(54.17M)(52.34M)(26.43M)(17.41M)
Pre-Tax Margin59.6%-3604.7%-13351.8%-4670.1%-240.1%
Income Tax Expense1.33M0000
Net Income122.83M(54.17M)(52.34M)(26.43M)(17.41M)
Net Margin58.9%-3604.7%-13351.8%-4670.1%-240.1%
EPS (Basic)1.78(0.77)(0.74)(0.37)(0.24)
EPS (Diluted)1.76(0.77)(0.74)(0.37)(0.24)
Weighted Avg Shares67.48M70.43M70.58M70.91M73.74M
Weighted Avg Shares (Diluted)68.07M70.43M70.58M70.91M73.74M

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.